Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-γ and catalase activities

European Journal of Pharmacology

Volumn 638, Issue 1-3, 2010, Pages 108-114

  Dhaunsi, Gursev S ^a   Yousif, Mariam H M ^a   Akhtar, Saghir ^a   Chappell, Mark C ^b   Diz, Debra I ^b   Benter, Ibrahim F ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin; Diabetes; Hypertension; Kidney

Indexed keywords

ANGIOTENSIN[1-7]; APOCYNIN; CATALASE; ENDOTHELIN 1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STREPTOZOCIN; ACETOPHENONE DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; GLUCOSE BLOOD LEVEL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; HYPERGLYCEMIA; HYPERTENSION; KIDNEY; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENOVASCULAR DISEASE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; RENAL ARTERY; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ACETOPHENONES; ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BLOOD GLUCOSE; BLOOD PRESSURE; CATALASE; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIN-1; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HYPERGLYCEMIA; HYPERTENSION; KIDNEY; MALE; NADPH OXIDASE; PEPTIDE FRAGMENTS; PPAR GAMMA; PROTEINURIA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENAL ARTERY;

EID: 77953541274     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.04.030     Document Type: Article

References (43)

1. Alexis J.D., Wang N., Che W., Lerner-Marmarosh N., Sahni A., Korshunov V.A., Zou Y., Ding B., Yan C., Berk B.C., Abe J.I. Bcr kinase activation by angiotensin II inhibits peroxisome proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells. Circ. Res. 2009, 104:69-78.
2. Asaba K., Tojo A., Onozato M.L., Goto A., Quinn M.T., Fujita T., Wilcox C.S. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 2005, 67:1890-1898.
3. Baudhuin P., Beaufay Y., Rahman L., Sellinger O., Wattiaux R., Jacques P., de Duve C. Tissue fractionation studies. Biochem. J. 1964, 92:179-184.
4. Benter I.F., Diz D.I., Ferrario C.M. Cardiovascular actions of angiotensin-(1-7). Peptides 1993, 14:679-684.
5. Benter I.F., Yousif M.H., Anim J.T., Cojocel C., Diz D.I. Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME. Am. J. Physiol. Heart. Circ. Physiol. 2006, 290:H684-H691.
6. Benter I.F., Yousif M.H., Cojocel C., Al-Maghrebi M., Diz D.I. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am. J. Physiol. Heart. Circ. Physiol. 2007, 292:H666-H672.
7. Benter I.F., Yousif M.H., Dhaunsi G.S., Kaur J., Chappell M.C., Diz D.I. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 2008, 28:25-33.
8. Bidani A.L., Picken M., Hacioglu R., Williamson G., Griffin K.A. Spontaneously reduced BP load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance. Am. J. Physiol. Renal Physiol. 2006, 288:F353-F362.
9. Brezniceanu M.L., Liu F., Wei C.C., Chénier I., Godin N., Zhang S.L., Filep J.G., Ingelfinger J.R., Chan J.S. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 2008, 57:451-459.
10. Brezniceanu M.L., Liu F., Wei C.C., Tran S., Sachetelli S., Zhang S.L., Guo D.F., Filep J.G., Ingelfinger J.R., Chan J.S. Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice. Kidney Int. 2007, 71:912-923.
11. Campbell T.W. The clinical significance of PPAR gamma agonism. Curr. Mol. Med. 2005, 5:349-363.
12. Chappell M.C. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?. Hypertension 2007, 50:596-599.
13. Da Ros R., Assaloni R., Ceriello A. Molecular targets of diabetic vascular complications and potential new drugs. Curr. Drug Targets 2005, 6:503-509.
14. Day B.J. Catalase and glutathione peroxidase mimics. Biochem. Pharmacol. 2009, 77:285-296.
15. Duan S.Z., Usher M.G., Mortensen R.M. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ. Res. 2008, 102:283-294.
16. Efrati S., Berman S., Chachashvili A., Cohen N., Averbukh Z., Weissgarten J. Rosiglitazone treatment attenuates expression of inflammatory hallmarks in the remaining kidney following contralateral nephrectomy. Am. J. Nephrol. 2008, 28:238-245.
17. Erbe D.V., Gartrell K., Zhang Y.L., Suri V., Kirincich S.J., Will S., Perreault M., Wang S., Tobin J.F. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul. Pharmacol. 2006, 45:154-162.
18. Etgen G.J., Mantlo N. PPAR ligands for metabolic disorders. Curr. Top. Med. Chem. 2003, 3:1649-1661.
19. Fogo A.B. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Curr. Opin. Nephrol. Hypertens. 2008, 17:282-285.
20. Frey R.S., Ushio-Fukai M., Malik A. NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology. Antioxid. Redox. Signal. 2009, 11:791-810.
21. Gervois P., Fruchart J.C., Staels B. Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARalpha and PPARgamma agonists. Int. J. Clin. Pract. Suppl. 2004, 43:22-29.
22. Góth L., Eaton J.W. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 2000, 356:1820-1821.
23. Góth L. Catalase deficiency and type 2 diabetes. Diabetes Care 2008, 31(12):e93.
24. Haidara M.A., Mikhailidis D.P., Rateb M.A., Ahmed Z.A., Yassin H.Z., Ibrahim I.M., Rashed L.A. Evaluation of the effect of oxidative stress and vitamin E supplementation onrenal function in rats with streptozotocin-induced Type 1 diabetes. J. Diabetes Complications 2009, 23:130-136.
25. Hayashi T., Juliet P.A., Kano-Hayashi H., Tsunekawa T., Dingqunfang D., Sumi D., Matsui-Hirai H., Fukatsu A., Iguchi A. NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction. Diabetes Obes. Metab. 2005, 7:334-343.
26. Houstis N., Rosen E.D., Lander E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440:944-948.
27. Ikejima H., Imanishi T., Tsujioka H., Kuroi A., Kobayashi K., Shiomi M., Muragaki Y., Mochizuki S., Goto M., Yoshida K., Akasaka T. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. J. Hypertens. 2008, 26:964-972.
28. Imanishi T., Kuroi A., Ikejima H., Kobayashi K., Mochizuki S., Goto M., Yoshida K., Akasaka T. Effects of pioglitazone on nitric oxide bioavailability measured using a catheter-type nitric oxide sensor in angiotensin II-infusion rabbit. Hypertens. Res. 2008, 31:117-125.
29. Koitka A., Cooper M.E., Thomas M.C., Tikellis C. Angiotensin converting enzyme 2 in the kidney. Clin. Exp. Pharmacol. Physiol. 2008, 35:420-425.
30. Kumagai S., Kai Y., Hanada H., Uezono K., Sasaki H. Relationships of the systolic blood pressure response during exercise with insulin resistance, obesity, and endurance fitness in men with type 2 diabetes mellitus. Metabolism 2002, 5:1247-1252.
31. Kurtz T.W. Beyond the classic angiotensin-receptor-blocker profile. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:S19-S26.
32. Kurtz T.W., Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the rennin-angiotensin system. J. Hypertens. 2004, 22:2253-2261.
33. Locatelli F., Canaud B., Eckardt K.U., Stenvinkel P., Wanner C., Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol. Dial. Transplant. 2003, 18:1272-1280.
34. Nistala R., Whaley-Connell A., Sowers J.R. Redox control of renal function and hypertension. Antioxid. Redox. Signal. 2008, 10:2047-2089.
35. Ruan X., Zheng F., Guan Y. PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal. Physiol. 2008, 294:F1032-F1047.
36. Small G., Burdett K., Connock M. A sensitive spectrophotometric assay for peroxisomal acyl CoA oxidase. Biochem. J. 1985, 227:205-210.
37. Smeets P.J., Planavila A., van der Vusse G.J., van Bilsen M. Peroxisome proliferators-activated receptors and inflammation: take it to heart. Acta. Physiol. (oxf) 2007, 191:171-188.
38. Soler M.J., Wysocki J., Ye M., Lloveras J., Kanwar Y., Batlle D. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney. Int. 2007, 72:614-623.
39. Touyz R.M., Schiffrin E.L. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical applications. Vasc. Pharmacol. 2006, 45:19-28.
40. Unger T., Stoppelhaar M. Rationale for double rennin-angiotensin-aldosterone system blockade. Am. J. Cardiol. 2007, 100:25J-31J.
41. Wolin M.S. Reactive oxygen species and the control of vascular function. Am. J. Physiol. Heart. Circ. Physiol. 2009, 296:H539-H549.
42. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Protein Pept. Lett. 2008, 15:850-853.
43. Yousefipour Z., Hercule H., Truong L., Oyekan A., Newaz M. Ciglitazone, a peroxisome proliferator-activated receptor gamma inducer, ameliorates renal preglomerular production and activity of angiotensin II and thromboxane A2 in glycerol-induced acute renal failure. J. Pharmacol. Exp. Ther. 2007, 322:461-468.